Abbott Laboratories
NYSE:ABT
Abbott Laboratories
Cash Equivalents
Abbott Laboratories
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbott Laboratories
NYSE:ABT
|
Cash Equivalents
$6.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash Equivalents
$1.2B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-3%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash Equivalents
$865m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
43%
|
CAGR 10-Years
15%
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash Equivalents
$1.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
Stryker Corp
NYSE:SYK
|
Cash Equivalents
$2.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
8%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash Equivalents
$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
30%
|
CAGR 10-Years
11%
|
See Also
What is Abbott Laboratories's Cash Equivalents?
Cash Equivalents
6.9B
USD
Based on the financial report for Dec 31, 2023, Abbott Laboratories's Cash Equivalents amounts to 6.9B USD.
What is Abbott Laboratories's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
7%
Over the last year, the Cash Equivalents growth was -30%.